EuroPCR 2022: Lifetime management is an important question for the evolution of TAVI

1498

Matti Adam (Cologne, Germany) talks to Cardiovascular News about the evolution of transcatheter aortic valve implantation (TAVI) and important areas of research in the field.

“There are a couple of unmet needs while we further evolve this technology,” says Adam, who adds that we need to find out what these patients need for better lifetime management.

Adam is speaking at EuroPCR 2022 (17–20 May, Paris, France) where he presented first real-world data from the use of the Trilogy (JenaValve) TAVI valve system in patients with aortic stenosis.


LEAVE A REPLY

Please enter your comment!
Please enter your name here